BLTE vs. ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, and AKRO
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
Belite Bio vs. Its Competitors
Elanco Animal Health (NYSE:ELAN) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 0.9% of Elanco Animal Health shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Elanco Animal Health has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500.
Elanco Animal Health has a net margin of 8.43% compared to Belite Bio's net margin of 0.00%. Elanco Animal Health's return on equity of 7.54% beat Belite Bio's return on equity.
Elanco Animal Health has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Elanco Animal Health currently has a consensus price target of $15.33, indicating a potential upside of 3.95%. Belite Bio has a consensus price target of $96.67, indicating a potential upside of 60.79%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts plainly believe Belite Bio is more favorable than Elanco Animal Health.
In the previous week, Elanco Animal Health had 6 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Elanco Animal Health and 4 mentions for Belite Bio. Elanco Animal Health's average media sentiment score of 0.43 beat Belite Bio's score of 0.39 indicating that Elanco Animal Health is being referred to more favorably in the media.
Summary
Elanco Animal Health beats Belite Bio on 11 of the 14 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
This page (NASDAQ:BLTE) was last updated on 7/9/2025 by MarketBeat.com Staff
Free BLTE Stock Alerts